These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6431814)

  • 1. Pulmonary function in hemophiliac patients treated with commercial factor VIII concentrates.
    Chediak J; Chausow A; Solarski A; Telfer MC
    Am J Med; 1984 Aug; 77(2):293-6. PubMed ID: 6431814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary function abnormalities after infusion of antihemophilic factor (AHF) concentrates.
    Boese EC; Tantum KR; Eyster ME
    Am J Med; 1979 Sep; 67(3):474-6. PubMed ID: 474593
    [No Abstract]   [Full Text] [Related]  

  • 3. Analysis of contaminants in factor VIII preparations administered to patients with hemophilia.
    Rock GA; Farrah G; Rozon G; Smiley RK; Cole R; Villeneuve D; Tittley P
    Can Med Assoc J; 1983 Feb; 128(4):403-8. PubMed ID: 6401585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophiliac with hemolytic anemia resulting from factor VIII concentrate.
    Soni NS; Patel AR; Vohra RM; Shah PC
    Acta Haematol; 1977; 58(5):294-7. PubMed ID: 413305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marijuana smoking as cause of reduction in single-breath carbon monoxide diffusing capacity.
    Tilles DS; Goldenheim PD; Johnson DC; Mendelson JH; Mello NK; Hales CA
    Am J Med; 1986 Apr; 80(4):601-6. PubMed ID: 3963040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HTLV-III seropositivity in European haemophiliacs exposed to Factor VIII concentrate imported from the USA.
    Melbye M; Froebel KS; Madhok R; Biggar RJ; Sarin PS; Stenbjerg S; Lowe GD; Forbes CD; Goedert JJ; Gallo RC
    Lancet; 1984 Dec; 2(8417-8418):1444-6. PubMed ID: 6151053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group.
    Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU; Purcell RH
    Ann Intern Med; 1994 Jan; 120(1):1-7. PubMed ID: 7504424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Suppression of factor VIII inhibitor in children with hemophilia A].
    Zenz W; Muntean W
    Padiatr Padol; 1987; 22(4):345-52. PubMed ID: 3125510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
    Hsu HC; Chen YF; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaphylactic reactions following infusion of factor VIII in a patient with classic hemophilia.
    Helmer RE; Alperin JB; Yunginger JW; Grant JA
    Am J Med; 1980 Dec; 69(6):953-7. PubMed ID: 6160766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single breath diffusing capacity for carbon monoxide: effects of adjustment for inspired volume dead space, carbon dioxide, hemoglobin and carboxyhemoglobin.
    Viegi G; Baldi S; Begliomini E; Ferdeghini EM; Pistelli F
    Respiration; 1998; 65(1):56-62. PubMed ID: 9523369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions.
    Schimpf K; Mannucci PM; Kreutz W; Brackmann HH; Auerswald G; Ciavarella N; Mösseler J; DeRosa V; Kraus B; Brueckmann C
    N Engl J Med; 1987 Apr; 316(15):918-22. PubMed ID: 3102963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of response to commercial factor VIII concentrate in hemophilia A.
    Rodgers GM; Ford MH
    Am J Hematol; 1991 Aug; 37(4):288. PubMed ID: 1907098
    [No Abstract]   [Full Text] [Related]  

  • 15. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low recovery in vivo of highly purified factor VIII in patients with hemophilia.
    Manno CS; Butler RB; Cohen AR
    J Pediatr; 1992 Nov; 121(5 Pt 1):814-8. PubMed ID: 1432437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic dysfunction in patients with classic hemophilia receiving lyophilized factor VIII concentrates and cryoprecipitate.
    Tsoukas C; Gervais F; Fuks A; Guttmann RD; Strawczynski H; Shuster J; Gold P
    Can Med Assoc J; 1983 Oct; 129(7):713-7. PubMed ID: 6225504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of salbutamol on the measurement of single-breath diffusing capacity.
    Yang J; Stanton J; Wang L; Beckert L; Frampton C; Burton D; Swanney MP
    Respirology; 2013 Nov; 18(8):1223-9. PubMed ID: 23701193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic differences among bovine and porcine Factor VIII concentrates.
    Edson JR; Swinehart CD
    Am J Clin Pathol; 1976 Jun; 65(6):957-63. PubMed ID: 59540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of the type of factor VIII concentrate on the CD4 lymphocyte count in hemophiliacs with human immunodeficiency virus infection: the results of a meta-analysis].
    Montoro Ronsano JB; Oliveras Martín J; Tusell Puigbert JM
    Med Clin (Barc); 1994 Nov; 103(18):690-4. PubMed ID: 7808075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.